Physician profile
Flora Eunhee Lim
NPI 1821699521
$3,319.59
in general payments reported to CMS, 2019-2025
14 companies · $1,169 in 2025
The $1,169 reported for 2025 was more than what 89% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $364 · 2022: $347 · 2023: $463 · 2024: $977 · 2025: $1,169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,608.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,132.14 | 2021-2025 | |
| Amgen INC. | $924.44 | 2022-2025 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $392.62 | 2023-2025 | |
| Lilly USA, LLC | $210.87 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Exact Sciences Corporation | $126.57 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $115.90 | 2025 | Gemtesa |
| Ironwood Pharmaceuticals, INC | $85.83 | 2024-2025 | |
| Esperion Therapeutics, INC. | $72.24 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.90 | 2023-2024 | Jardiance |
| Scilex Pharmaceuticals INC. | $63.81 | 2024-2025 | |
| Shield Therapeutics INC | $49.86 | 2024-2025 | |
| Gilead Sciences, INC. | $26.89 | 2025 | |
| Phathom Pharmaceuticals, INC. | $24.64 | 2024 | Voquezna |
| Azurity Pharmaceuticals, INC. | $22.88 | 2025 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Flora Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.